In the last three months, Agilent Technologies (A) stock has risen from $61.14 on June 27, 2018, to $70.33 in September 2018.
The enterprise value of Agilent is $22.11 billion, and its enterprise-value-to-revenue ratio is 4.6x. The stock is trading at a forward PE multiple of 23.68x. Its price-to-sales ratio is 4.66x, and its price-to-book ratio is 4.92x. The company has generated EBITDA per share of $3.45 in fiscal 2017 compared to $2.57 in fiscal 2015. That’s expected to increase to $4.03 in fiscal 2019.
Its current ratio, a metric of how effectively a company can meet its short-term obligations, stands at 3.6x. In comparison, the current ratios for its peers Medtronic (MDT), Stryker SYK), and Thermo Fisher Scientific (TMO) are 2.50x, 1.80x, and 1.60x, respectively, indicating that it’s in a better position to meet its short-term obligation than its peers.
Of the 14 analysts covering Agilent Technologies in September, 13 of them have given Agilent stock a “buy” or higher rating, and one has given it a “hold.” The mean rating for Agilent stock is 1.64 with a target price of $78.43, implying an upside potential of 11.5% over its closing price of $70.33 on September 26.
In comparison, analysts have given Medtronic (MDT), Stryker (SYK), and Thermo Fisher Scientific (TMO) mean ratings of 2.24, 1.93, and 1.63, respectively, and target prices of $102.45, $184.43, and $252.86, respectively.